Development of a Single-Shot Subunit Vaccine for HIV-1. 3. Effect of Adjuvant and Immunization Schedule on the Duration of the Humoral Immune Response to Recombinant MN gp120
- 1 December 1996
- journal article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 85 (12) , 1350-1357
- https://doi.org/10.1021/js960329b
Abstract
HIV-1 prophylaxis may require "sterilizing immunity" (i.e., the prevention of infection), and this is likely to demand a vaccine that gives high, long-lasting antibody titers. Although it is known that vaccine adjuvants and immunization schedule affect the magnitude of the immune response, there are few reports on antibody decay rates and persistence. Guinea pigs were immunized with recombinant gp120 using different adjuvants and immunization schedules, and the anti-gp120 and HIV-1 neutralization titers were determined over time following the last booster immunization. As observed previously in the literature, a longer time between boosting gave higher titers, with a slight increase in the decay half-life as the booster was spaced farther out from the primary immunization. The decay rate of the antibody titers showed surprisingly little effect of adjuvant, except for sustained-release polymer-based formulations. Adjuvants that gave high titers initially after boosting showed the greatest persistence of antibody titers (persistence defined as the residual titers at long times). These data show that high, long-lasting titers may be achieved by using sustained-release formulations, and these are likely the prime vaccine candidates for prophylaxis requiring prolonged sterilizing immunity.Keywords
This publication has 32 references indexed in Scilit:
- Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea PigsAIDS Research and Human Retroviruses, 1995
- Comparison of the immune response to recombinant gp120 in humans and chimpanzeesAIDS, 1994
- Hepatitis A vaccination: Schedule for accelerated immunizationVaccine, 1992
- Monoclonal Antibodies to the Extracellular Domain of HIV-1IIIB gp160 that Neutralize Infectivity, Block Binding to CD4, and React with Diverse IsolatesAIDS Research and Human Retroviruses, 1992
- Impaired Response to Recombinant Hepatitis B Vaccine in HIV-Infected PersonsJournal of Clinical Gastroenterology, 1992
- Effect of Dose and Immunization Schedule on Immune Response of Baboons to Recombinant Glycoprotein 120 of HIV-1The Journal of Infectious Diseases, 1989
- Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptorCell, 1987
- INDUCTION OF LONG-TERM IMMUNITY TO PARALYTIC POLIOMYELITIS BY USE OF NON-INFECTIOUS VACCINEThe Lancet, 1984
- Immunizations: Current controversiesThe Journal of Pediatrics, 1982
- Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly.BMJ, 1977